Shanghai Medicilon Inc. (SHA:688202)
China · Delayed Price · Currency is CNY 107.64
+3.68 (3.54%)
At close: Sep 30, 2026
Shanghai Medicilon Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,384 | 1,163 | 1,037 | 1,366 | 1,659 | 1,167 |
Other Revenue | 0.09 | 0.12 | 0.46 | 0.03 | 0.06 | 0.76 |
| 1,384 | 1,163 | 1,038 | 1,366 | 1,659 | 1,167 | |
Revenue Growth | 30.98% | 12.08% | -24.01% | -17.68% | 42.12% | 75.28% |
Cost of Revenue | 1,063 | 970.53 | 1,008 | 1,060 | 983.57 | 639.5 |
Gross Profit | 321.45 | 192.53 | 30.04 | 305.74 | 675.36 | 527.76 |
Selling, General & Admin | 215.92 | 205.43 | 191.65 | 220.18 | 204.09 | 132.28 |
Research & Development | 108.94 | 104.41 | 96.73 | 122.39 | 122.88 | 77.76 |
Other Operating Expenses | 11.02 | 1.24 | 3.01 | 3.28 | 2.28 | 0.73 |
Operating Expenses | 427.9 | 377.31 | 401.84 | 389.92 | 352.76 | 219.29 |
Operating Income | -106.45 | -184.78 | -371.8 | -84.17 | 322.6 | 308.47 |
Interest Expense | -7.6 | -9.51 | -8.36 | -9.66 | -4.88 | -2.01 |
Interest & Investment Income | 13.66 | 15.95 | 20.19 | 8.86 | 4.6 | 7.41 |
Currency Exchange Gain (Loss) | -12.62 | -3.96 | 7.59 | -0.32 | 12.39 | -3.57 |
Other Non Operating Income (Expenses) | -1.24 | -1.16 | -12.08 | -0.4 | 0.04 | -0.79 |
EBT Excluding Unusual Items | -114.25 | -183.45 | -364.47 | -85.69 | 334.74 | 309.51 |
Gain (Loss) on Sale of Investments | 2.39 | 3.73 | -5.13 | 3.23 | - | - |
Gain (Loss) on Sale of Assets | -1.84 | -1.95 | -1.12 | -0.34 | -0.87 | -1.04 |
Asset Writedown | -5.13 | -5.13 | -18.42 | - | - | - |
Other Unusual Items | 8 | 1.81 | 8.07 | 23.69 | 34.25 | 14.44 |
Pretax Income | -110.83 | -185 | -381.08 | -59.1 | 368.11 | 322.91 |
Income Tax Expense | -7.5 | -17.17 | -50.23 | -25.89 | 29.87 | 38.26 |
Earnings From Continuing Operations | -103.33 | -167.83 | -330.85 | -33.21 | 338.24 | 284.65 |
Minority Interest in Earnings | - | - | - | - | - | -2.42 |
Net Income | -103.33 | -167.83 | -330.85 | -33.21 | 338.24 | 282.22 |
Net Income to Common | -103.33 | -167.83 | -330.85 | -33.21 | 338.24 | 282.22 |
Net Income Growth | - | - | - | - | 19.85% | 118.12% |
Shares Outstanding (Basic) | 134 | 132 | 134 | 128 | 122 | 122 |
Shares Outstanding (Diluted) | 134 | 132 | 134 | 128 | 122 | 122 |
Shares Change | 2.22% | -1.34% | 4.86% | 4.98% | 0.08% | 0.19% |
EPS (Basic) | -0.77 | -1.27 | -2.47 | -0.26 | 2.78 | 2.32 |
EPS (Diluted) | -0.77 | -1.27 | -2.47 | -0.26 | 2.78 | 2.32 |
EPS Growth | - | - | - | - | 19.75% | 117.71% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 17.79 | 36.14 | -133.14 | -152.36 | -425.39 | 160.22 |
Free Cash Flow Per Share | 0.13 | 0.27 | -0.99 | -1.19 | -3.50 | 1.32 |
Dividend Per Share | - | - | - | - | 0.279 | 0.699 |
Dividend Growth | - | - | - | - | -60.14% | 117.49% |
Gross Margin | 23.22% | 16.55% | 2.90% | 22.39% | 40.71% | 45.21% |
Operating Margin | -7.69% | -15.89% | -35.83% | -6.16% | 19.45% | 26.43% |
Profit Margin | -7.46% | -14.43% | -31.88% | -2.43% | 20.39% | 24.18% |
Free Cash Flow Margin | 1.29% | 3.11% | -12.83% | -11.16% | -25.64% | 13.73% |
EBITDA | -13.99 | -93.71 | -279.52 | 1.36 | 384.14 | 354.49 |
EBITDA Margin | -1.01% | -8.06% | -26.94% | 0.10% | 23.16% | 30.37% |
D&A For EBITDA | 92.46 | 91.08 | 92.28 | 85.53 | 61.54 | 46.01 |
EBIT | -106.45 | -184.78 | -371.8 | -84.17 | 322.6 | 308.47 |
EBIT Margin | -7.69% | -15.89% | -35.83% | -6.16% | 19.45% | 26.43% |
Effective Tax Rate | - | - | - | - | 8.11% | 11.85% |
Revenue as Reported | 1,384 | 1,163 | 1,038 | 1,366 | 1,659 | 1,167 |